DAIICHI SANKYO CO., LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5,010 JPY | +5.12% |
|
+8.07% | +29.39% |
| 04-25 | Scholz pledges further support for the pharmaceutical industry | DP |
| 04-25 | Daiichi Sankyo's Attributable Profit Soars 84% in Fiscal 2024 | MT |
| Sales 2024 | 1,602B 10.11B 810B | Sales 2025 * | 1,753B 11.07B 886B | Capitalization | 9,607B 60.65B 4,857B |
|---|---|---|---|---|---|
| Net income 2024 | 201B 1.27B 101B | Net income 2025 * | 185B 1.17B 93.62B | EV / Sales 2024 | 5.72 x |
| Net cash position 2024 * | 556B 3.51B 281B | Net cash position 2025 * | 455B 2.87B 230B | EV / Sales 2025 * | 5.22 x |
| P/E ratio 2024 |
45.6
x | P/E ratio 2025 * |
50.1
x | Employees | 17,435 |
| Yield 2024 * |
0.9% | Yield 2025 * |
1.13% | Free-Float | 97.04% |
More Fundamentals
* Assessed data
More news
Latest transcript on Daiichi Sankyo Co., Ltd.
More recommendations
More press releases
More news
| 1 day | +5.12% | ||
| 1 week | +8.07% | ||
| Current month | +4.88% | ||
| 1 month | +2.75% | ||
| 3 months | +16.97% | ||
| 6 months | +24.47% | ||
| Current year | +29.39% |
1 week
4 592.00
5 058.00
1 month
4 443.005 058.00
Current year
3 847.005 173.00
1 year
3 566.005 173.00
3 years
1 981.005 173.00
5 years
1 731.005 173.00
10 years
518.675 173.00
| Managers | Title | Age | Since |
|---|---|---|---|
Sunao Manabe
CEO | Chief Executive Officer | 69 | 31/03/07 |
Hiroyuki Okuzawa
PSD | President | 61 | 31/03/17 |
Ken Takeshita
CTO | Chief Tech/Sci/R&D Officer | - | 31/03/21 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sawako Nohara
BRD | Director/Board Member | 66 | 31/05/19 |
Kazuaki Kama
BRD | Director/Board Member | 75 | 31/05/19 |
Sunao Manabe
CEO | Chief Executive Officer | 69 | 31/03/07 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 25.16% | 15 M€ | +7.34% | ||
| 4.18% | 251 M€ | +13.17% | ||
| 3.32% | 174 M€ | -.--% | - | |
| 3.32% | 51 M€ | -.--% | - | |
| 3.24% | 15 M€ | +14.10% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 5,010 | +5.12% | 9,590,300 |
| 25/04/24 | 4,766 | +0.78% | 8,225,700 |
| 24/04/24 | 4,729 | +1.42% | 4,048,900 |
| 23/04/24 | 4,663 | +0.65% | 3,096,100 |
| 22/04/24 | 4,633 | -0.06% | 3,202,900 |
Delayed Quote Japan Exchange, April 26, 2024 at 07:00 am
More quotes
Daiichi Sankyo Company specializes in developing, manufacturing and marketing pharmaceutical products. Net sales break down by activity as follows:
- sale of medicines (99.8%): prescription medicines (92.8% of net sales) and OTC medicines (7.2%) primarily for the treatment of thrombotic disorders, tumors, diabetes and rheumatoid arthritis;
- other (0.2%): primarily real estate activities.
Net sales are distributed geographically as follows: Japan (64.1%), North America (17.2%), Europe (9.7%) and other (9%).
Sector
Pharmaceuticals
Calendar
30/07/2024
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
5,010
JPY
Average target price
5,673
JPY
Spread / Average Target
+13.24%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +29.39% | 61.03B | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- 4568 Stock
